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Abstract
Based on a molecular classiﬁcation of prostate cancer using gene expression pathway signatures, we derived a set of
48 genes in critical pathways that signiﬁcantly predicts clinical outcome in all tested patient cohorts. We tested these
genes in a functional genomics screen in a panel of three prostate cancer cell lines (LNCaP, PC3, DU145), using RNA
interference. The screen revealed several genes whose knockdown caused strong growth inhibition in all cell lines.
Additionally, we tested the gene set in the presence of docetaxel to see whether any gene exhibited additive or
synergistic effects with the drug. We observed a strong synergistic effect between DLGAP5 knockdown and docetaxel
in the androgen-sensitive line LNCaP, but not in the two other androgen-independent lines. We then tested whether
this effect was connected to androgen pathways and found that knockdown of the androgen receptor by si-RNA
attenuated the synergy signiﬁcantly. Similarly, androgen desensitized LNCaP-AI cells had a higher IC50 to docetaxel and
did not exhibit the synergistic interaction. Short-term exposure to enzalutamide did not signiﬁcantly alter the
behaviour of parental LNCaP cells. An immunoﬂuorescence analysis in LNCaP cells suggests that under the double
insult of DLGAP5 knockdown and docetaxel, cells predominantly arrest in metaphase. In contrast, the knockdown of
the androgen receptor by siRNA appears to assist cells to progress through metaphase in to anaphase, even in the
presence of docetaxel. Our data suggest that DLGAP5 has a unique function in stabilizing spindle formation and
surviving microtubule assault from docetaxel, in an androgen-regulated cell cycle system.
Introduction
Prostate cancer is a common disease—the third most
common cancer in males—that is characterized clinically
by a wide diversity of outcomes. While a large fraction of
patients has indolent, localized and manageable disease,
there is a smaller subset of patients that suffer from
aggressive forms with lethal metastatic potential. Until
recently, initial treatments including surgery, radiation,
androgen deprivation therapy (ADT), and anti-androgen
therapy, were followed by chemotherapy once recurrence
set in. After two large-scale clinical trials (CHAARTED,
STAMPEDE) showed beneﬁts for combined treatments in
advanced tumours1, chemotherapy, commonly with the
agent docetaxel (DCT), can now be used together with
ADT as an initial treatment for higher-grade tumours.
However, while the improved guidelines extend the life of
patients with aggressive prostate cancer, there is still no
cure for this disease. Furthermore, while a multitude of
clinical trials is underway to test other therapeutic agents
in prostate cancer, at the time of writing DCT remains the
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most widespread chemotherapy that patients receive and
the only standard recommendation.
Here we aim to explore further options to target the
aggressive, lethal form of prostate cancer. To this end, we
make use of a molecular classiﬁcation of prostate cancer
based on gene expression data that we established pre-
viously2. This classiﬁcation system identiﬁes a subtype of
highly aggressive tumours with poor outcomes, char-
acterized by gene expression signatures for embryonic
and induced pluripotent stem cells (ESC, iPSC), and
for loss of function of the tumour suppressors PTEN and
p53. This ESC|PTEN-|p53- subtype is opposed to a
normal-like subtype with a good prognosis, deﬁned by
differentiation and functional PTEN and p53 pathway
signatures. We hypothesize that the ESC|PTEN-|p53-
subtype may contain molecular features that make these
tumours both more prone to metastasis and more resis-
tant to therapies. We selected genes highly enriched in the
ESC|PTEN-|p53- subgroup relative to the normal-like
subgroup across several patient data sets. From these we
curated a small set of 48 genes that were also associated
with p53 function, cell cycle mechanics or stemness. We
then utilised a functional genomics screen to test these
genes in three metastatic prostate cancer lines, with and
without the addition of DCT. Data analysis aimed to
identify genes whose knockdown would either sig-
niﬁcantly inhibit the growth of the cell lines in general, or
whose knockdown would be synergistic with DCT.
Results
A 48 gene signature predicts aggressive prostate cancer
In order to determine genes that may affect outcomes in
aggressive prostate cancer (PCa) we applied our pre-
viously developed classiﬁcation scheme2 to data from
three large PCa patient cohorts with associated survival
outcomes (TCGA-PRAD, GSE21034, GSE16560)3–5. The
classiﬁcation scheme in particular detects an aggressive
subtype that is characterized by the expression of pathway
signatures indicating loss of PTEN or activation of the
PI3K-AKT pathway, loss of p53 function, and stemness as
indicated by loss of differentiation signals and gain of
embryonic stem cell signatures (ESC|PTEN-|p53- sub-
type). The combination of these characteristic pathway
enrichments effectively predicts malignant cancer and
poor clinical outcome2. To collect these signatures into a
more usable predictive gene set, we compared the ESC|
PTEN-|p53- subtype in each cohort to the subtype with
the opposite signature pattern, a ‘normal-like’ subgroup
with a signature proﬁle indicating differentiation and
intact p53 and PTEN function. Differential expression
analysis across all three sets produced a list of 233 genes
most signiﬁcantly enriched in ESC|PTEN-|p53- tumours
versus normal-like tumours (see Methods, compare
Fig. 1a). As expected, the list contained a large number of
genes associated with cell proliferation. In order to focus
our gene set on the characteristic pathways, we manually
curated a subset of 48 genes using a keyword search on
the extended GeneCards annotation, with keywords
comprising terms such as ‘apoptosis’, ‘stem cell’ and
‘meiosis’ (see Methods). Proliferation genes were sub-
selected for direct mechanistic function in the cell cycle
and function within the PTEN-AKT/PI3K pathway. The
ﬁnal list is shown in Table 1. We evaluated the 48 gene list
as a predictive signature on the three data sets and an
additional patient data set with clinical annotation6–9,
using single-sample gene set enrichment analysis
(ssGSEA). The resulting scores for each data set were
clustered into three groups (high, intermediate, low sig-
nature scores). A high score effectively predicted poor
patient outcome in all sets (Fig. 1b). The gene set was also
expressed at signiﬁcantly higher levels in castration
resistant prostate cancer (CRPCa) (Fig. 1c, upper left), and
metastatic disease compared to primary PCa (Fig. 1c,
upper right, Supp Fig. 1A, left), in distant metastatic
samples compared to prostate recurrent disease (Fig. 1c,
lower right, Supp Fig. 1A, right) and in high Gleason
grade tumours (Fig. 1c, lower left), overall supporting the
idea that these genes might contribute to metastatic
potential, as well as treatment resistance (early recur-
rence, castration resistance). In addition, expression for all
individual genes in the set was highly correlated in all data
sets. This ensures in particular that individual genes in the
list have a similar predictive value as the set (compare
Table 2). We would like to point out here that the list of
48 genes was not derived as the most effective predictor of
survival. Instead, we tried to focus on crucial pathways
that might contribute directly and mechanistically to
aggressive features.
Functional genomics screen of 48 genes reveals novel
growth inhibitors in aggressive PCa models
We tested the 48 genes in a functional genomics assay
using siRNA knockdown in a panel of three PCa cell lines
with aggressive features; LNCaP, PC3 and DU145
(Fig. 1a). Of these, only LNCaP cells are androgen sensi-
tive with an intact active androgen receptor (AR), and
wild-type p53. All three lines are defective in PTEN. The
PC3 and DU145 lines served as models for metastatic
disease, while LNCaP was included to model the differ-
ence towards androgen-sensitive disease. We performed a
viability screen using commercially available sets of four
individual siRNAs per gene (‘deconvoluted’ screen, cell
count assay, see Methods). Deconvolution does not
exclude false negative results, but may help pinpointing
off-target effects. The screen was performed with two
arms, where DCT or vehicle (DMSO) was added after 24
h. Data from the vehicle arm were evaluated for genes that
affect growth across the three cell lines. A gene was
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considered signiﬁcant if its knockdown caused growth
inhibition (GI) above mean plus standard deviation in at
least two sequences and in at least two cell lines (Fig. 1d,
e). si-PLK1 served as a positive control and was the top hit
with GI > 78% in more than two sequences in all cell lines
(PLK1 satisﬁed signiﬁcance requirements in our human
data analysis; its knockdown also inhibits growth effec-
tively in many cancer cell lines10,11). The top two most
Fig. 1 Functional genomics screen of 48 genes in aggressive prostate cancer a Schematic representation of gene selection and screen design.
DCT, docetaxel. b The 48 gene set was evaluated for outcome prediction from (recurrence-free) survival data from four prostate cancer cohorts.
Patient samples were clustered into three groups (kmeans) based on ssGSEA scores for the 48 gene set. Groups with high scores are shown in red,
intermediate in grey and low in blue. Each plot is inset with a heatmap showing the clustering of scores. Logrank p-values (high versus low) are
annotated in plots. c Mean expression of all 48 genes was used to plot differences by sample type. The gene set is highly expressed in castration-
resistant prostate cancer (CRPCa, upper left), metastatic PCa (upper right), distant metastases (lower right), and high-Gleason PCa (lower left). Overall
ANOVA p-values are annotated in the plots. d Heatmap illustrating screening results in DMSO condition. Columns are sorted into cell lines indicated
on top, four individual siRNAs per gene (si-1/2/3/4) and three replicates. A full red colour indicates 100% growth inhibition relative to NTC, a blue
colour indicates negative growth inhibition (GI). Genes are sorted top to bottom by increasing overall mean GI. e Average GI values for six genes of
interest (mean of experiments+ SEM, n= 3)
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effective growth inhibitory genes identiﬁed in the screen
were TPX2 ( > 70% GI, 2+ siRNAs) and RRM2 ( > 55% GI,
2+ siRNAs, Fig. 1e). Both are unsurprising candidates as
drivers of growth, since they are essential in mitosis, and
in DNA duplication, respectively. Interestingly however,
knockdown of Denticleless E3 Ubiquitin Protein Ligase
Homologue (DTL) also showed good results in all cell
lines with a GI > 40% in 2+ sequences (Fig. 1e, panel
centre bottom). DTL is part of the DCX (DDB1-CUL4-X-
box) complex that is required for cell cycle control, and
particularly for DNA damage response and repair. DTL
has been implicated in gastric tumour growth and inva-
sion, and in ovarian cancers12,13. Furthermore, knock-
down of sperm associated antigen 5 (SPAG5), a gene
associated with spermatogenesis and mitosis regulation,
had a pronounced effect in PC3 and DU145 cells,
demonstrating GI > 50% in both with at least two siRNAs:
it was less effective in LNCaP cells by a factor two (Fig. 1e,
panel top right). This result is supported by a recent
animal study showing that SPAG5 is upregulated in
metastatic but not primary prostate tumours, and that its
knockdown reduces tumour growth and metastasis
in vivo14. Based on our results, one might speculate that
this SPAG5 activity is linked with either the androgen
status of the tumour cells, or their p53 status. Conversely
RAD51 knockdown produced a GI of 60% in LNCaPs,
with approximately half that in the other cell lines (Fig. 1e,
panel bottom right). RAD51 is a DNA damage response
gene that has been associated with resistance to radiation
and PARP inhibitors in PCa, and is co-regulated by p5315–17.
Overall, the GI assay in DMSO detected both known PCa
associated genes, as well as an interesting candidate not
previously associated with PCa (DTL).
Functional genomics screen in the presence of DCT reveals
cell cycle genes CDC20, TPX2 and DLGAP5
The 48 genes in the signature are highly expressed in
metastatic and recurrent tumours (Fig. 1c). These tumour
types are candidates for chemotherapy in the clinic. We
therefore sought to test whether knockdown of any of
these genes added to the effect of treatment with DCT,
the standard chemotherapeutic agent in PCa and CRPCa.
DCT was given at EC30 in each cell line (LNCaP, 1.8 nM,
PC3, 1.36 nM, DU145, 3.28 nM) for 48 h. The results
showed a moderate effect overall, with little difference in
GI observed ±DCT (Mean %GI all genes, LNCaP,
+DCT= 24.6%, −DCT= 19.8%: PC3,+DCT= 25.2%,
−DCT= 24.2%: DU145,+DCT= 14.2%, −DCT=
23.1%). The effect of gene knockdown in vehicle treated
cells was subtracted from those treated with DCT to
generate a ‘window’ of efﬁcacy. Again, little difference in
overall window was observed between cell lines (mean+
sd, all genes LNCaP −4.80+ 16.71, DU145 -3.54+ 11.97,
PC3 −1.02+ 9.57, Fig. 2a). To identify candidates, genes




APOBEC3B 9582 Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3B
ASF1B 55723 Anti-silencing function 1B histone
chaperone
AURKB 9212 Aurora kinase B
BIRC5 332 Baculoviral IAP repeat- containing 5
BUB1B 701 BUB1 mitotic checkpoint serine/
threonine kinase B
CDC20 991 Cell division cycle 20
CDCA5 113130 Cell division cycle associated 5
CDCA8 55143 Cell division cycle associated 8
CDKN3 1033 Cyclin-dependent kinase inhibitor 3
CEP55 55165 Centrosomal protein 55 kDa
DEPDC1B 55789 DEP domain containing 1B
DIP2B 57609 DIP2 disco-interacting protein 2
homologue B (Drosophila)
DLGAP5 9787 Discs, large (Drosophila) homologue-
associated protein 5
DNMT3B 1789 DNA (cytosine-5-)-methyltransferase 3
beta
DTL 51514 Denticleless E3 ubiquitin protein ligase
homologue (Drosophila)
EXO1 9156 Exonuclease 1
EZH2 2146 Enhancer of zeste homologue 2
(Drosophila)
FOXM1 2305 Forkhead box M1
GTSE1 51512 G-2 and S-phase expressed 1
HJURP 55355 Holliday junction recognition protein
IQGAP3 128239 IQ motif containing GTPase activating
protein 3
KDM2B 84678 Lysine (K)-speciﬁc demethylase 2B
KDM5B 10765 Lysine (K)-speciﬁc demethylase 5B
KIAA0101 9768 KIAA0101
L2HGDH 79944 L-2-hydroxyglutarate dehydrogenase
LMNB1 4001 Lamin B1
LRPPRC 10128 Leucine-rich pentatricopeptide repeat
containing
MELK 9833 Maternal embryonic leucine zipper kinase
MYBL2 4605 v-myb avian myeloblastosis viral
oncogene homologue-like 2
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with a window ≥mean+ sd in 2+ cell lines and 2+ siR-
NAs were selected: these were CDC20, TPX2, MYBL2,
DLGAP5, SPAG5, and LMNB1. Of these, CDC20 and
TPX2 satisﬁed the criteria in all cell lines. Strikingly, ﬁve
of these six genes are directly involved in mitosis.
Knockdown of CDC20 had a window of GI > 10% in all
cell lines and three siRNAs (Fig. 2b, top panel). CDC20 is
part of the anaphase-promoting complex APC(CDC20),
and recent reports corroborate synergistic effects with
DCT in PCa18,19. We conﬁrmed the knockdown capacity
of the siRNAs by western blotting (Fig. 2c, e). Comparison
with GI in DMSO condition (Fig. 2b) suggested off-target
effects in some of the siRNAs. A validation growth assay
performed in PC3 cells (Incucyte assay evaluating con-
ﬂuency of cell populations over time, see Methods)
showed that one siRNA had a signiﬁcant added effect with
DCT (Fig. 2f). TPX2 knockdown also had an added effect
with DCT in all cell lines, in two siRNAs (Fig. 2b middle
panel). TPX2 binds with AURKA and is expressed during
mitosis, on the spindle microtubules emanating from the
poles20–22. Its expression along these forms a gradient
with the expression of another gene in the list, DLG
associated protein 5 (DLGAP5), which is expressed on the
chromatin side. The data for DLGAP5 suggested a strong
synergistic effect with DCT that only occurred in LNCaP
cells (Fig. 2b bottom panel). Because of the striking nature
of this result, we focused on investigating DLGAP5.
DLGAP5 knockdown is synergistic with DCT in LNCaP cells
We observed a strong synergistic effect between the
knockdown of DLGAP5 and DCT in LNCaP cells, but
not in PC3 or DU145 cells. This synergistic effect was
observed with three out of four individual siRNA
sequences (combination index by Bliss independence
model, CI < 0.635, stderr < 0.035, where CI < 1 signiﬁes
synergy, see Supp Fig. 1A, B), each of which achieved a
window > 45 percentage points, and resulted in > 60%
total GI in the presence of DCT (Fig. 2b bottom panel).
This is a near 5-fold change of GI (p < 0.001), compared to
a modest 1.3-fold change in PC3 and negative effect
observed in DU145 cells. Consistently, the three effective
siRNAs each produced an >80% knockdown of relative
protein content by western blotting, while the fourth was
ineffective (Fig. 2d, e bottom panels). We further con-
ﬁrmed the synergistic effect using an Incucyte growth
assay in LNCaP cells with different doses of DCT (Fig. 2g,
Supp Fig. 2C). The same three siRNAs were effective in
this assay. While the knockdown alone did not affect
growth signiﬁcantly, we observed a dramatic growth
reduction with addition of DCT at 1 nM, producing a
signiﬁcant divergence of relative growth curves (p < 0.01,
by AUC). Phenotypically, the cells appeared to undergo
growth arrest followed by apoptosis (rounding, blebbing,
Supp Fig. 1E). In PC3 cells, the Incucyte growth assay did
not reveal signiﬁcant added effects (0.5–3 nM DCT, data
not shown). For the remainder of the study we used a pool
of the three effective siRNAs, referred to as siDLGAP5.
DLGAP5-DCT synergy is attenuated by loss of AR function
In contrast to PC3 and DU145, LNCaP cells are
androgen-sensitive. We therefore tested whether the
synergistic effect would change under AR knockdown.
Combining siDLGAP5 and siAR attenuated the synergy
between DCT and DLGAP5 knockdown (Fig. 3a, sig-
niﬁcance measured by AUC). This was seen both in the
conﬂuency growth assays and a CytoxGreen cytotoxicity
assay performed in the Incucyte (Fig. 3b). Knockdown of
AR alone did not have a signiﬁcant effect on DCT sen-
sitivity, while DLGAP5 knockdown shifted the EC30 into
the sub-nanomolar range ( < 0.5 nM, 48 h DCT exposure,
Fig. 3c), with intermediate values for the double knock-
down (0.5 < EC30 < 1.0 nM). We then tested an AR inde-
pendent sub-line, LNCaP-AI, that was cultured in
charcoal-stripped hormone free medium. LNCaP-AI





NAA15 80155 N(alpha)-acetyltransferase 15, NatA
auxiliary subunit
NCAPG 64151 Non-SMC condensin I complex, subunit
G
PBK 55872 PDZ binding kinase
PLK1 5347 Polo-like kinase 1
PTTG1 9232 Pituitary tumour-transforming 1
RAD51 5888 RAD51 recombinase
RAD54L 8438 RAD54-like (S. cerevisiae)
RRM2 6241 Ribonucleotide reductase M2
SPAG5 10615 Sperm associated antigen 5
TET3 200424 Tet methylcytosine dioxygenase 3
TK1 7083 Thymidine kinase 1, soluble
TMEM97 27346 Transmembrane protein 97
TOP2A 7153 Topoisomerase (DNA) II alpha 170 kDa
TPX2 22974 TPX2, microtubule-associated
TRIP13 9319 Thyroid hormone receptor interactor 13
TROAP 10024 Trophinin associated protein
TTK 7272 TTK protein kinase
UBE2C 11065 Ubiquitin-conjugating enzyme E2C
UHRF1 29128 Ubiquitin-like with PHD and ring ﬁnger
domains 1
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Table 2 Correlation and prognostic values of the 48 genes
Analysis Correlation: 7 data sets Survival: logrank high vs low, tertiles
Gene Mean PCC Stderr PCC Mean log10(PV) TCGA GSE21034 GSE16560 GSE25136
APOBEC3B 0.4856 0.0656 10.0992 1.71E-03 1.35E-01 2.04E-01 2.11E-02
ASF1B 0.8587 0.0325 42.3520 3.34E-04 1.25E-02 na 4.91E-01
AURKB 0.6929 0.0714 21.6256 5.58E-03 8.57E-03 na 3.59E-01
BIRC5 0.8350 0.0360 43.6592 3.33E-04 1.10E-03 7.25E-07 7.92E-02
BUB1B 0.8192 0.0593 47.0013 7.69E-04 1.76E-03 2.42E-02 1.54E-01
CDC20 0.7861 0.0787 37.6874 2.95E-05 4.01E-04 4.95E-02 1.18E-01
CDCA5 0.9218 0.0053 60.1906 3.67E-06 3.35E-03 na na
CDCA8 0.8701 0.0486 50.5426 1.50E-04 6.42E-03 na 4.30E-01
CDKN3 0.8370 0.0317 43.7493 4.53E-03 5.89E-05 4.39E-04 6.98E-02
CEP55 0.8610 0.0418 48.5437 2.40E-03 2.92E-03 na 1.85E-01
DEPDC1B 0.8575 0.0280 49.0341 7.68E-03 5.62E-04 na na
DIP2B 0.2916 0.0909 4.6882 4.87E-01 4.23E-01 na na
DLGAP5 0.9002 0.0219 56.1288 4.81E-04 1.80E-04 na 2.65E-01
DNMT3B 0.6054 0.0372 15.7632 1.59E-03 9.30E-02 na 3.55E-01
DTL 0.8058 0.0435 42.5223 2.13E-03 3.76E-04 na 3.02E-01
EXO1 0.8281 0.0500 46.2383 2.23E-04 7.67E-03 na 2.84E-01
EZH2 0.7299 0.0609 28.9437 3.91E-04 8.41E-02 1.10E-02 7.81E-02
FOXM1 0.8335 0.0627 48.5116 1.13E-03 4.23E-04 3.88E-03 2.13E-01
GTSE1 0.6820 0.1217 26.8985 8.75E-05 1.08E-03 1.76E-01 1.25E-01
HJURP 0.7048 0.0814 20.2463 2.79E-04 9.97E-02 na 4.75E-01
IQGAP3 0.6107 0.1535 22.2494 2.42E-04 4.65E-04 na na
KDM2B 0.4024 0.0749 9.5927 3.72E-01 2.97E-02 na na
KDM5B 0.2053 0.1030 3.1869 1.40E-01 3.65E-01 na 9.14E-03
KIAA0101 0.7584 0.0641 32.3947 1.38E-03 4.84E-03 3.58E-03 7.48E-04
L2HGDH 0.2832 0.0595 3.3340 1.91E-01 1.80E-01 na 6.02E-02
LMNB1 0.7537 0.0679 35.3260 8.35E-04 8.12E-03 2.35E-03 2.89E-01
LRPPRC 0.1656 0.0661 2.0329 8.44E-03 2.58E-01 4.59E-02 7.25E-03
MELK 0.8342 0.0617 49.5800 3.21E-03 5.06E-05 3.22E-02 2.03E-04
MYBL2 0.7365 0.0773 32.5805 9.75E-06 2.61E-04 4.22E-02 1.45E-01
NAA15 0.2681 0.0687 3.6134 4.18E-01 na na 7.01E-02
NCAPG 0.8956 0.0387 59.2214 1.68E-04 8.05E-04 na 1.48E-01
PBK 0.8279 0.0386 42.1333 4.35E-05 5.63E-05 na 1.57E-02
PLK1 0.7966 0.0774 42.1368 2.77E-06 3.71E-04 2.14E-01 1.84E-01
PTTG1 0.8281 0.0344 42.8207 1.68E-03 2.82E-03 9.37E-05 2.78E-02
RAD51 0.6930 0.0941 27.9681 1.44E-02 2.89E-02 3.45E-01 4.06E-01
RAD54L 0.7185 0.0951 29.8411 5.19E-05 1.06E-02 1.01E-01 4.39E-02
RRM2 0.8386 0.0362 44.2879 1.54E-04 7.28E-05 8.74E-04 9.17E-05
SPAG5 0.8269 0.0643 47.5110 2.63E-07 1.02E-03 1.57E-03 2.29E-01
Hewit et al. Cell Death and Disease          (2018) 9:1069 Page 6 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
lower response rate at higher doses (EC40 > 4 nM com-
pared to < 2 nM in LNCaPs). Remarkably, the LNCaP-AI
cells did not respond synergistically to siDLGAP5+DCT
in this dose range (Fig. 3d). On the other hand, short-term
suppression of AR activity with the AR antagonist enza-
lutamide did not change the synergy effect of siDLGAP5
+DCT in LNCaPs (Fig. 3e). Similarly, switching LNCAP-
AI cells to regular medium supplemented with 10 nM
dihydrotestosterone (DHT) at transfection did not
reproduce the effect seen in the parental cells (Supp
Fig. 2B). We then tested whether AR knockdown had an
effect on DLGAP5 protein expression and vice versa, with
and without DCT (Fig. 3f, g). There was no signiﬁcant
difference in protein levels relative to control in either
case. Furthermore, DHT stimulation of LNCaPs increased
DLGAP5 protein levels only slightly (p > 0.1), consistent
with a small increase in mitotic rate (23.5%, measured by
CCNB1 levels, p > 0.1, Supp Fig. 2C, D). Microarray data
sets describing LNCaP cells stimulated by 24 h of 10 nM
DHT (GSE60721, GSE4636, GSE6933023–25) conﬁrmed a
slight increase of both DLGAP5 and CCNB1 (Supp
Fig. 2E). Taken together these data support an indirect
interaction between DLGAP5 and AR, rather than a direct
one.
DLGAP5-DCT synergy impacts metaphase, attenuated by
AR knockdown
Direct interaction between the AR and DLGAP5 proteins
is indeed unlikely given their expression patterns during
the cell cycle. DLGAP5 is strongly expressed during all
phases of mitosis, is located at the spindle microtubule26,27,
and is present at low levels during the remainder of the cell
cycle28. The AR protein is present and builds up during the
cycle but vanishes at the onset of mitosis where it remains
absent until division is complete29. We conﬁrmed this
effect in our cells, using an ICC/IF assay to analyse mitotic
health (Fig. 4a). The degradation of the AR during mitosis
was unaffected by DLGAP5 knockdown (Supp Fig. 2F).
Likewise, AR knockdown did not seem to suppress
expression of DLGAP5 at the mitotic spindle apparatus
(not shown). DLGAP5 is involved in microtubule organi-
sation during mitosis27,30. It is expressed on the kine-
tochores of spindle ﬁbres and has been implicated in the
nucleation of central spindle microtubules during ana-
phase28. The gradient it forms with TPX2 towards the
spindle poles during mitosis might also be involved in the
contraction of spindle microtubule in anaphase21. This
indicates that the metaphase-to-anaphase transition might
be critical in our setting. DCT arrests cells in metaphase,
and consistently we found that under DCT (0.5 nM), the
ratio of metaphase-to-post-metaphase mitotic cells was
decreased (Fig. 4b, c). This ratio decreased even further
under siDLGAP5+DCT (0.6FC to 0.4FC, Fig. 4d), sug-
gesting that the cells are predominantly arrested in meta-
phase in this condition. Interestingly, the ratio was
increased in siAR treated cells (Fig. 4c), and was not sig-
niﬁcantly changed by DCT in that condition (Fig. 4d). This
indicates that AR knockdown might help cells progress
through metaphase and initiate anaphase under DCT
insult.
Table 2 continued
Analysis Correlation: 7 data sets Survival: logrank high vs low, tertiles
Gene Mean PCC Stderr PCC Mean log10(PV) TCGA GSE21034 GSE16560 GSE25136
TET3 0.3346 0.0705 3.8902 1.85E-01 3.58E-01 na 5.47E-02
TK1 0.8103 0.0325 37.8871 1.07E-04 3.49E-02 1.32E-03 4.63E-01
TMEM97 0.4398 0.0693 9.7922 8.43E-02 8.45E-02 4.25E-02 3.90E-01
TOP2A 0.8044 0.0493 37.9232 1.20E-04 9.33E-04 3.32E-04 1.32E-02
TPX2 0.8554 0.0752 56.1147 2.00E-06 3.63E-04 2.05E-01 3.11E-01
TRIP13 0.6271 0.1025 25.6237 1.23E-03 3.19E-02 2.17E-05 2.76E-01
TROAP 0.7652 0.0682 29.6392 2.06E-05 2.15E-02 7.45E-03 4.81E-01
TTK 0.6963 0.0593 29.1810 5.31E-03 1.58E-03 3.78E-01 2.38E-01
UBE2C 0.8870 0.0318 59.0475 5.03E-06 6.06E-04 3.86E-03 1.31E-01
UHRF1 0.8612 0.0150 43.4272 4.80E-05 2.91E-03 na na
Pearson correlation coefﬁcients (PCC) between individual gene expression and the mean expression of the 48 gene set were calculated in seven data sets (TCGA,
GSE21034, GSE16560, GSE25136, GSE35988, SU2C, FHCC). Average PCC and standard errors are listed, along with the average –log10(p-value) of the correlations.
Survival columns contain logrank p-values for Kaplan–Meier analyses for individual genes, calculated by splitting each data set into tertiles based on expression, and
comparing high versus low tertiles. Note that in GSE25136 this yields lower p-values due to the small size of groups (n= 79)
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Discussion
Recent large-scale clinical trials (STAMPEDE,
CHAARTED) have shown that advanced prostate cancers
respond better to a ﬁrst-line combination of chemother-
apy (DCT) and ADT than to the sequential treatment
where ADT is given ﬁrst and chemotherapy is given upon
recurrence. However, while the clinical beneﬁts of earlier
chemotherapeutic intervention are clear from these
trials1, advanced prostate cancer is still a lethal disease
and further improvements are urgently needed. The trial
data seems to suggest earlier, more aggressive interven-
tion for the most aggressive tumours; this would suggest
an early point of action also for future targeted therapies
and novel combination approaches. The data also
emphasizes the importance of androgen status for treat-
ment efﬁcacy and supports treating ADT-naïve tumours
with complementary (i.e. non-hormone) therapy. Here we
have analysed a set of 48 genes that were selected based
on their expression and potential function in a highly
aggressive, molecularly deﬁned subgroup of human can-
cer samples. We have evaluated knockdown of these
genes in models of advanced PCa including both
androgen-independent and -sensitive cell lines. Especially
in the above context, the present results suggest an
interesting novel interaction between the androgen
receptor system and mitotic dynamics under DCT. We
have shown here that loss of the mitotic gene DLGAP5
acutely sensitizes androgen-dependent LNCaP cells to
Fig. 2 Results from the synergy screen with docetaxel. a Heatmap illustrating the results from the docetaxel (DCT) synergy screen. Columns are
sorted as before. The colours show %GI under DCT relative to DMSO (window). A full red colour indicates a positive window of 50 percentage points,
a green colour indicates a negative window. b Individual data for CDC20, TPX2 and DLGAP5. In blue, growth inhibition in DMSO, relative to NTC (four
siRNAs, three cell lines; shown is mean of experiments+ SEM, n= 3). In green, growth inhibition in DCT relative to NTC in DCT. c, d, e Knockdown
validation by western blot, performed in PC3 cells for the 4 individual siRNAs targeting CDC20 (c, e top panels) and performed in LNCaP cells for the
siRNAs targeting DLGAP5 (d, e bottom panels). f, g Validation of growth inhibition by Incucyte growth assay. Growth was measured by area of
conﬂuence, values shown are treatment condition relative to DMSO condition, mean of experiments+ SEM (n= 2). CDC20 validation was performed
in PC3 cells (f), DLGAP5 validation was performed in LNCaP cells (g)
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DCT treatment. This effect is attenuated by knockdown
of the AR, and is absent in the androgen-independent
LNCaP-AI cell line variant, as well as in androgen-
independent PC3 and DU145 cells.
However, the effect is not attenuated under short-term
use of the AR antagonist enzalutamide and it is not re-
established in LNCaP-AI under acute exposure to hor-
mone. This suggests that only full transcriptional loss of
the AR, or long-term transformation to androgen inde-
pendence affect the DLGAP5-DCT synergy. We note here
that, while LNCaP-AI cells do express the AR, its down-
stream transcriptional activity is altered as the cells
become androgen independent and this affects in parti-
cular also cell cycle regulation31–33. This in turn seems to
suggest that cells with an active and well-established
androgen pathway rely on DLGAP5 to stabilize mitotic
health and function, while androgen-independent cells do
not nearly as much.
Our immunoﬂuorescence studies suggest that the cri-
tical phase of mitosis is the transition from meta- to
anaphase. Based on this data, the formation of central
spindle microtubule might be the point of vulnerability.
Others have shown that a considerable fraction of central
spindle microtubule is formed by DLGAP5, while another
Fig. 3 DLGAP5 knockdown synergizes with DCT in an androgen-dependent manner. a Incucyte growth assay: Growth was measured as area of
conﬂuency. Curves show growth inhibition of DCT treatment relative to DMSO, for two doses of DCT. Shown is mean of experiments+ SEM (n= 3).
DLGAP5 knockdown (pool of three siRNAs, blue curves) synergizes with DCT in this assay. The effect is attenuated by additional AR knockdown
(pool of four siRNAs, yellow curves). Signiﬁcance was calculated by comparing AUC followed by T-test (shown for 1.0 nM condition, right hand side).
*p < 0.05, **p < 0.01. b Toxicity assay with CytoxGreen shows a similar attenuation under AR knockdown. c Dose response curves at 48 h drug
exposure. d Dose response curves in androgen desensitized LNCaP-AI cells. In doses up to 4 nM DCT there is no signiﬁcant effect of DLGAP5. e Dose
response curves in parental LNCaP cells that were exposed to androgen inhibition by enzalutamide for 1 h prior to DCT exposure show no
attenuation. f, g Western blots for DLGAP5 and AR protein conﬁrm the knockdown effect of the siRNA pools, and show no signiﬁcant difference of
DLGAP5 and AR protein under AR and DLGAP5 knockdown, respectively
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part is recruited from remaining interphase micro-
tubule28. This latter part could be affected in androgen-
dependent cells, as androgen can suppress tubulin
expression and might affect spindle density34 and micro-
tubule nucleation at the centrosomes during interphase35.
Thus androgen-dependent cells without DLGAP5 might
be increasingly vulnerable to DCT simply because the
density of microtubule in their spindles and especially
their central spindles, is lower, requiring a lower molecule
content of drug to bind and stabilize the spindle micro-
tubule. In other words, in these cells, DLGAP5 might
make up for a lack of ambient microtubule to create
sufﬁciently thick spindle ﬁbre bundles (Fig. 4e). We are
currently expanding our ICC/IF studies to analyse spindle
density. DLGAP5 also has binding sites for several
androgen-regulated genes in its promoter region,
including most prominently SREBF1 and NCOR1, which
have been linked to cell-cycle regulation36–38. We are
currently investigating these potential regulatory
interactions.
This interaction between the androgen-regulated cell
cycle, DCT and DLGAP5 might also extend to other
cancers. As reported previously39, DLGAP5 levels alone
have predictive power in prostate cancer (Table 2).
However, the gene was ﬁrst found as a prognostic indi-
cator in hepatocellular carcinoma (HCC)40,41. HCC is
more common in males than in females (2.89-fold higher
incidence, 2.47-fold higher mortality, SEER
18 2011–2015, https://seer.cancer.gov/statfacts/html/
livibd.html), and numerous studies have investigated the
AR pathway in this disease42–47. In fact, DLGAP5 gene
expression very effectively predicts outcome in male HCC
Fig. 4 Androgen receptor knockdown might support transition of cells to anaphase phase, counteracting the DLGAP5 and DCT-induced
halt in metaphase. a Immunoﬂuorescence analysis of LNCaP cells transfected with NTC siRNA show the characteristic expression of DLGAP5 on the
kinetochore side of the mitotic spindle, while AR protein is depleted during mitosis. Scale bar, 20 μm. b Fields of LNCaP cells with DLGAP5 and AR
knockdown, respectively, with and without the addition of 0.5 nM DCT (12 h). AR knockdown led to a higher fraction of post-metaphase mitotic cells
(white arrows), in contrast to DLGAP5 knockdown, which led to a higher fraction of metaphase mitotic cells (yellow arrows) in DMSO, and a further
increase of metaphase cells in DCT. Scale bar, 50 μm. c Quantiﬁcation of counts ratios, post-metaphase relative to metaphase cells. Mean of
experiments+ SEM (n= 3). *p < 0.05, **p < 0.01. d Change of the post-metaphase/metaphase ratios in DCT versus DMSO in the different siRNA
conditions. Mean of experiments+ SEM (n= 2). *p < 0.05. e Schematic illustration of a proposed interaction between AR, DLGAP5 and DCT. In AR
sensitive cells, androgen might down-regulate tubulin expression, which in turn could affect the amount of microtubule (MT) carried over from
interphase into metaphase. During mitosis, DLGAP5 contributes to MT generation at the kinetochores and supports MT organization. DLGAP5 is
expressed strongly at the chromatin side of the spindle MT during meta-and anaphase (shaded in yellow). DCT interferes with MT dynamics during
this phase. Loss of DLGAP5 and an active AR system might both contribute to lower spindle density and weaker MT organisation, producing higher
sensitivity to DCT
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patients, but much less so in females (Supp Fig 3A, B, C).
DLGAP5 expression is not gender-biased in these
tumours (TCGA-LIHC, p= 0.52, n= 115 female, n= 239
male), suggesting that interaction networks and back-
ground might play a role in the gene’s functionality. The
gene is also a predictor of poor outcome in ER-positive
breast cancers, but not in ER-negative, or HER2-positive
ones (Supp Fig 3D, E, F), indicating again a
connection with hormone status.
Overall, here we show a novel feature of androgen-
sensitive prostate cancer cells compared to independent
or desensitized ones that might provide a potential new
synergistic target for androgen-sensitive, aggressive
prostate cancers that qualify for ﬁrst-line DCT treatment.
Methods
Cell culture
LNCaP, DU145 and PC3 were cultured in RPMI 1640
medium supplemented with glutamine and 10% fetal
bovine serum. LNCaP-AI cells were cultured in charcoal-
stripped DMEM medium minus phenol red.
siRNA transfection and screen
Human OnTarget plus siRNAs were ordered from
Horizon Discovery (Dharmacon), either individual
(screening library) or as pool (AR). Cells were transfected
with siRNAs using a reverse transfection protocol with
Lipofectamine RNAiMAX (Invitrogen), following the
manufacturer’s instructions. The same protocol was used
for all cell lines transfected with siRNA.
Viability screen
SiRNA screening was performed in triplicate with a
custom library of 48 human genes, and a set of four
individual siRNAs per gene (Horizon). Cell stocks were
grown to conﬂuency, harvested, counted and seeded in
96-well plates at the following densities to reﬂect differing
growth rates: PC3 at 3000 cells per well (cpw), DU145 at
2500 cpw and LNCaP at 5000 cpw. A reverse transfection
method was used in order to transfect cells with siRNA.
Subsequently cell suspensions were added to the plates
using an XRD automated reagent dispenser (FluidX).
Plates were incubated at 37 °C, 5% CO2 for 24 h, after
which either EC30 DCT (PC3: 1.36 nM), (DU145: 3.28
nM), (LNCaP: 1.80 nM) or DMSO was added to cells.
After incubation for a further 48 h, the medium was
removed and cells were ﬁxed with 4% formaldehyde and
stained with DAPI/Tx-100 in 1x PBS (0.25 µg/ml/0.001%
ﬁnal concentration/well). Images of nuclei were acquired
using the Operetta High Content Imaging system (Per-
kinElmer) and the number of nuclei in each well were
quantiﬁed as a measure of cell growth using Columbus
High Content Imaging and Analysis Software
(PerkinElmer).
Incucyte growth assay
Cells were seeded in 96-well Greiner black glass bottom
plates (Greiner 665090), and transfected with siRNA at
seeding where needed. Depending on cell type, wells were
seeded with 5000 to 12000cpw in 100 ul medium. Plates
were incubated overnight and transferred to the Incucyte.
Drugs were added with additional 50 ul medium (spike-in)
between scans. CytoxGreen reagent was added according
to manufacturer’s protocol along with drugs, where
required. In each experiment, plates contained three or
more replicate wells per condition and two pictures were
taken per well per scan. Conﬂuence data were down-
loaded, plotted and analysed using MATLAB custom
routines. In particular, for relative GI, we ﬁrst normalized
conﬂuence growth curves by the conﬂuence at time of
drug addition in order to balance out variation in seeding.
We then calculated the ratios of conﬂuence measures for
drug over DMSO for each condition, in each experiment.
We then plotted the mean of experiments with the SEM
indicated in error bars. In order to analyse differences
between the curves we calculated area under curves and
compared these values using a Student’s T-test.
Western blots
Cells were seeded in 6-well plates and transfected at
seeding as needed. Cells were seeded at 300,000 cpw in
2000 ul medium. Cells were incubated overnight and
drugs (DMSO, DCT) were added in additional medium
(200 ul) and were left on for required periods (24 h). Cells
were washed once with PBS and lysed in buffer (50 mM
TRIS ph7.5, 0.5% SDS) with cOmplete Mini preparation
(Roche). Lysates were collected in Qiagen shredder col-
umns (Qiashredder) and centrifuged through the column
for 2 min at high speed. Lysates were buffered in NuPage
LDS sample buffer with 5% mercaptoethanol, and heated
to 100 °C for 5 min. Western blotting was performed
using the NuPage system, with NuPage Bis-Tris 4–12%
precast gels. Gels were run in MES buffer (NuPage MES
SDS running buffer, 135 V, 80 min), and were transferred
onto nitrocellulose membranes (GE Healthcare Amer-
sham Protran 0.2NC) in NuPage transfer buffer plus 20%
methanol (100 V, 90 min). Membranes were stained with
Poinceau solution, washed in TBS, blocked in 5% milk in
TBS for 1 h and incubated with primary antibodies (see
below) at manufacturer’s recommended concentrations
overnight. Blots were washed with TBS and incubated
with secondary antibodies (Licor) for 1 h. Blots were
washed in TBS followed by distilled water and were
screened on Licor System. Licor software was used to
perform quantitation.
Antibodies:
CDC20: CDC20 (D6C2Q) Rabbit mAB #14866, Cell
Signaling Technology
DLGAP5: HPA005546, Sigma Aldrich
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AR: AR(441):sc-7305, Santa Cruz Biotechnology
TUB: Anti-Tubulin Antibody YL1/2 ab6160, abcam
CCNB1: Anti-Cyclin B1 Antibody ab32053,
abcamFKBP5: FKBP5 (D5G2) Rabbit mAB #12210, Cell
Signaling Technology
GAPDH: GAPDH Rabbit PolyAB CatNo 10494-1-AB,
Proteintech Europe
ICC/IF
For immunoﬂuorescence, LNCaP cells were plated on
Greiner black myClear Cellstar 96-well plates (Greiner
655090) and were transfected with siRNA at seeding. Cells
were seeded at 12,000 cpw. After incubation for 36 h,
0.5 nM DCT or DMSO was added to the wells and plates
were incubated for an additional 12 h. Cells were then
washed once with PBS and ﬁxed in 4% para-formaldehyde
for 20min. Plates were washed three times in PBS,
blocked for 1 h in PFS (0.5 L PBS, 3.5 g ﬁsh skin gelatin,
1.25 mL 10% saponin stock) and incubated with primary
antibodies (DLGAP5, AR, TUB, same as above) in PFS at
manufacturer’s recommended doses overnight. Cells were
washed in PFS and incubated with secondary antibodies
(Alexa 488, 594, 647, DAPI) in PFS for 1 h. After another
round of washing, wells were ﬁlled with 200 ul PBS and
plates were screened using the Opera system at ×20 and
×63 resolution. Images were analysed using the system
software (Columbus High Content Imaging and Analysis
Software, PerkinElmer). Meta- and post-metaphase cell
counts were performed manually using the ×20 resolution
images with Tubulin and DAPI channels (36 image ﬁelds
per well, three replicate wells per condition per experi-
ment). Ratios of post-meta/metaphase cells were calcu-
lated for each well, ratios were averaged over replicate
wells in each experiment, and mean of experiments was
plotted with error bars indicating SEM.
Computational analyses
Gene expression data were downloaded from the Gene
Expression Omnibus (GEO) (GSE21034, GSE16560,
GSE25136, GSE35988, GSE44905, GSE60721, GSE4636,
GSE69330) and from The Cancer Genome Atlas (TCGA)
portal (TCGA-PRAD). TCGA, GSE21034 and GSE16560
data sets were classiﬁed using our previously described
classiﬁcation scheme2. In short, gene expression sig-
natures characterizing ESC, iPSC, PRC2 targets, p53 status
(p53+ , p53−), PTEN status (PTEN+ , PTEN−), MYC
status (MYC upregulated), RAS pathway, Cytokines,
TMPRSS2-ERG fusion, Mesenchyme, Proneural and
Proliferation, were analysed using single-sample GSEA
(ssGSEA)48 on each sample in a data set, resulting in an
array of 14 signature scores per sample. The signature
score arrays were then clustered using an unsupervised
clustering algorithm that applies several clustering rou-
tines and a range of cluster numbers and determines the
optimal clustering using a Bayesian arbiter (best ﬁt to a
mixed Gaussian data model). In all three data sets, we
found a cluster that was highly associated with the ESC,
PTEN− and p53− signatures as well as with proliferation
signatures (Proliferation, MYC), and a group with the
opposite signals. In each of the three data sets, the dif-
ferential expression of all individual genes was calculated
on these groups (stem-like versus normal-like). To com-
pare these across data sets, since not all genes were
represented on all platforms, we designated a gene to be
signiﬁcant if it satisﬁed a signiﬁcance cutoff in at least two
data sets. For the resulting list of genes, GeneCard
annotation was downloaded and searched for terms: cell
cycle, PI3K, p53, DNA repair, DNA damage, stem cell,
meiosis and spermatogenesis. This included a search of
the literature annotations associated with each gene in
addition to its descriptors. Genes were also evaluated for
their expression in the cell lines PC3, DU145 and LNCaP
using data from GSE21034, GSE44905 and internal
RNASeq data (Hing Leung). Genes were included in the
ﬁnal list based on an evaluation of their p-values of
enrichment in the data sets, their expression (present) in
the cell lines, and their annotations. To evaluate the list of
48 genes as a signature, we used ssGSEA to calculate
signature scores for each sample in a set, and then clus-
tered the scores into three groups using kmeans. Survival
data was then analysed using Kaplan–Meier analysis and
logrank p-values. It was tested in a fourth cohort6. Mean
expression of the gene set was used to test differential
expression in sample types in additional gene sets7–9 and
ANOVA p-values were calculated using MATLAB stan-
dard script. All data were handled using Matlab and Unix
shell script.
Statistical analyses
Screening data were analysed for quality control, and Z
prime scores were calculated for each plate using the
Dotmatics Studies software (all Z prime scores were
greater than 0.5). Each plate contained eight samples
negative and positive controls (siNTC, siAS). The median
of the eight negative controls on each plate was used to
calculate sample values for the siRNA probes (value=
(median(siNTC)− SAMPLE) / (median(siNTC)) × 100).
Mean of three experiments was calculated for each cell
line, each gene, each sequence and each condition
(DMSO, DCT). Window sizes were calculated across all
genes and sequences in a given cell line, and mean plus
two standard deviations was used as a cutoff to determine
signiﬁcant sequences. Genes with two or more signiﬁcant
sequences were considered signiﬁcant in that cell line.
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Furthermore, combination indices (CI) were calculated
using the Bliss independence model, for each gene,
sequence and experiment in each cell line. For each cell
line, we plotted the distribution of all CI scores and
determined the 0.05 quantile in order to obtain a sig-
niﬁcance value relative to the screening data.
Incucyte data were downloaded as percent conﬂuence
in phase and green channels (CytoxGreen). Mean of
technical replicates (three or more wells per condition,
two images per well per scan) was used for all calculations
and data were normalized by the conﬂuency at time of
drug addition for all conditions. Relative GI curves were
then calculated as DCT/DMSO and plotted using mean of
experiments and error of means. Signiﬁcant differences
between groups of curves were determined by calculating
AUC using the trapezoidal rule for each curve, followed
by Student’s T-test.
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